Expression of plasmid-mediated resistance genes ESBLs and PMQR among uropathogens, isolated from non-dialysis CKD patients with pyelonephritis

Authors

  • O.І. Chub Medical Center “Rishon”, Kharkiv, Ukraine; Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine https://orcid.org/0000-0002-7279-1935
  • S.V. Teslenko Limited Liability Company “Medlux”, Kharkiv, Ukraine
  • O.V. Chub Municipal Non-Profit Enterprise “City Clinical Hospital № 19” of Kharkiv City Council, Kharkiv, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.11.1.2022.354

Keywords:

urinary tract infections, pyelonephritis, chronic kidney disease, antibiotics, resistance, plasmids, ESBLs, PMQR

Abstract

Urinary tract infections (UTIs) are thought to be the most common group of bacterial infections, worldwide. It is estimated that the proportion of UTIs remains at a high level reaching 150 million episodes per year worldwide and accounting for $6 billion in health care expenditures. In USA more than 100,000 hospital admissions per year are the UTIs patients, among them the patients with pyelonephritis are the most frequent. For the US outpatients, approximately 15 % of antibiotics used are prescribed for UTIs. However, recent studies in Europe and the United States have demonstrated a steady increase in the rate of uropathogen resistance to commonly prescribed antibiotics, and this obviously will lead to a reduction in therapeutic possibilities of UTI. CDC has estimated that more thаn 2 million infections and 23,000 deaths are due to antibiotic resistance each year. By 2050, it is estimated, that antibiotic resistance will cause 10 million deaths every year. Infection is an importаnt cause of mоrbidity and mоrtality amоng patients with kidney failurе and is the sеcond lеading causе of death following CVD. At the EU/EEA level, more than half (54 %) of the E.coli isolates reported to EARS-Net for 2020 were resistant to at least one of the antimicrobial groups under regular surveillance, i.e. aminopenicillins, fluoroquinolones, third-generation cephalosporins, aminoglycosides and carbapenems. A majority (87.4 %) of the third-generation cephalosporin-resistant E.coli isolates from 2020 were extended-spectrum beta-lactamase (ESBL) positive. Use of broad-spectrum antimicrobials is a known risk factor for colonization and spread of resistant Enterobacteriaceae, including E.coli. The high levels of ESBLs and increasing resistance to key antimicrobial groups might also lead to an increased consumption of carbapenems, which in turn can increase the selection pressure and facilitated the spread of carbapenem-resistant Enterobacteriaceae. The article presents data on the antibacterial susceptibility of isolated uropathogens, and their association with the presence or absence of plasmid-mediated resistance genes ESBLs and PMQR.

Downloads

Download data is not yet available.

References

Kolman KB. Cystitis and Pyelonephritis: Diagnosis, Treatment, and Prevention. Prim Care. 2019 Jun;46(2):191-202. doi: 10.1016/j.pop.2019.01.001.

Pietrucha-Dilanchian P, Hooton TM. Diagnosis, Treatment, and Prevention of Urinary Tract Infection. Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.UTI-0021-2015.

Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar;28(1):1-13. doi: 10.1016/j.idc.2013.09.003.

American Urology Association. Medical Student Curriculum: Adult UTI. 2019. Available from: https://www.auanet.org/education/adult-uti.cfm

Waller TA, Pantin SAL, Yenior AL, Pujalte GGA. Urinary Tract Infection Antibiotic Resistance in the United States. Prim Care. 2018 Sep;45(3):455-466. doi: 10.1016/j.pop.2018.05.005.

Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017 Mar;129(2):242-258. doi: 10.1080/00325481.2017.1246055.

Centres for Disease Control and Prevention. 2019 Antibiotic Resistance Threats Report. Available from: https://www.cdc.gov/drugresistance/resources/publications.html .

WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe; 2022.

Ribero Pombo MH, Gandra S, Thompson D, Lamkang A, Pulcini C, Laxminarayan R. Global Core Standards for Hospital Antimicrobial Stewardship Programs: International Perspectives and Future Directions. Doha, Qatar: World Innovation Summit for Health; 2018. 52 p.

Bonkat G, Bartoletti R, Bruyère F, et al. EAU Guidelines on Urological Infections. European Association of Urology; 2022. 78 p.

KDIGO. Clinical practice guideline for evaluation and management of CKD. KDIGO Public Review Draft: 2012; 150 p.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement: CLSI document M100-S23. USA Pennsylvania: Clinical and Laboratory Standards Institute; 2013.

Sundsfjord A, Simonsen GS, Haldorsen BC, et al. Genetic methods for detection of antimicrobial resistance. APMIS. 2004 Nov-Dec;112(11-12):815-37. doi: 10.1111/j.1600-0463.2004.apm11211-1208.x.

Li PK, Garcia-Garcia G, Lui SF, et al; World Kidney Day Steering Committee. Kidney Health for Everyone, Everywhere-from prevention to detection and equitable access to care. Nephrol Dial Transplant. 2020 Mar 1;35(3):367-374. doi: 10.1093/ndt/gfz283.

Published

2022-05-24

How to Cite

Chub, O., Teslenko, S., & Chub, O. (2022). Expression of plasmid-mediated resistance genes ESBLs and PMQR among uropathogens, isolated from non-dialysis CKD patients with pyelonephritis. KIDNEYS, 11(1), 10–18. https://doi.org/10.22141/2307-1257.11.1.2022.354

Issue

Section

Original Articles